Akt inhibitors: mechanism of action and implications for anticancer therapeutics

被引:30
|
作者
Bhutani, Jaikrit [1 ]
Sheikh, Asfandyar [2 ,4 ]
Niazi, Asfandyar Khan [3 ]
机构
[1] Post Grad Inst Med Sci, Rohtak, Haryana, India
[2] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan
[3] Shifa Coll Med, Islamabad, Pakistan
[4] Pakistan Res Evolut Sci Soc, Karachi 74200, Pakistan
来源
关键词
SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-SURVIVAL; KINASE; GROWTH; CARCINOMAS; EXPRESSION; ONCOGENE; PATHWAY; GLIOBLASTOMAS;
D O I
10.1186/1750-9378-8-49
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and transcription. Akt1 gene amplification has been implicated in gastric carcinoma while Akt2 amplification has been linked with ovarian, pancreas, breast and stomach tumors. The use of Akt inhibitors as monotherapy or in combination with other anticancer drugs could be useful for combating drug resistance and improving response. Thus, comprehensive understanding of Akt and its linked signaling pathways (PI3K, PKB, mTOR etc.) is necessary to lead to newer drug development and use.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Akt inhibitors: mechanism of action and implications for anticancer therapeutics
    Jaikrit Bhutani
    Asfandyar Sheikh
    Asfandyar Khan Niazi
    Infectious Agents and Cancer, 8
  • [2] PARP inhibitors: current status and implications for anticancer therapeutics
    Usmani, Hadi
    Hussain, Syed Ather
    Sheikh, Asfandyar
    INFECTIOUS AGENTS AND CANCER, 2013, 8
  • [3] PARP inhibitors: current status and implications for anticancer therapeutics
    Hadi Usmani
    Syed Ather Hussain
    Asfandyar Sheikh
    Infectious Agents and Cancer, 8
  • [4] Recent Development of Anticancer Therapeutics Targeting Akt
    Morrow, John K.
    Du-Cuny, Lei
    Chen, Lu
    Meuillet, Emmanuelle J.
    Mash, Eugene A.
    Powis, Garth
    Zhang, Shuxing
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (01) : 146 - 159
  • [5] Matrix metalloproteinase inhibitors as anticancer therapeutics
    Mannello, F
    Tonti, G
    Papa, S
    CURRENT CANCER DRUG TARGETS, 2005, 5 (04) : 285 - 298
  • [6] Histone deacetylase inhibitors as novel anticancer therapeutics
    Walkinshaw, D. R.
    Yang, X. J.
    CURRENT ONCOLOGY, 2008, 15 (05) : 237 - 243
  • [7] Carbonic Anhydrase Inhibitors: Possible Anticancer Drugs With a Novel Mechanism of Action
    Supuran, Claudiu T.
    DRUG DEVELOPMENT RESEARCH, 2008, 69 (06) : 297 - 303
  • [8] Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics
    Law, Mary E.
    Corsino, Patrick E.
    Narayan, Satya
    Law, Brian K.
    MOLECULAR PHARMACOLOGY, 2015, 88 (05) : 846 - 852
  • [9] Hypoxia inducible factor pathway inhibitors as anticancer therapeutics
    Burroughs, Sarah K.
    Kaluz, Stefan
    Wang, Danzhu
    Wang, Ke
    Van Meir, Erwin G.
    Wang, Binghe
    FUTURE MEDICINAL CHEMISTRY, 2013, 5 (05) : 553 - 572
  • [10] Discovery and the mechanism of action of novel selective carbonic anhydrase IX inhibitors for anticancer therapy
    Kazokaite, J.
    Janoniene, A.
    Petrikaite, V.
    Matuliene, J.
    Matulis, D.
    FEBS JOURNAL, 2017, 284 : 337 - 337